Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Sinobiopharma Signs Deal for New Hypertension Drug

publication date: Aug 12, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Sinobiopharma, Inc., a US-headquartered company that operates entirely in China, will co-develop, manufacture and commercialize Eplerenone, with Jiangsu Lianhuan Pharmaceuticals Co. Eplerenone is an aldosterone antagonist used as an adjunct to treat hypertension and heart failure. Sinobiopharma will receive 60% of the profits. More details....

Stock Symbol: (OTCBB: SNBP)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at this event:
 
 
Hope to see you there!
 
ChinaBio® Events
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors